myeloproliferative neoplasms

myeloproliferative neoplasms

[mī′əlōprōlif′ərətiv′]
a family of chronic malignant bone marrow and blood diseases caused by mutations that generate clones of myelocytic or erythrocytic precursors and platelet precursors. Diseases include chronic myelogenous leukemia, polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
References in periodicals archive ?
M2 EQUITYBITES-January 24, 2018-QIAGEN wins US FDA clearance for first-ever JAK2 Test for use in diagnosis of additional myeloproliferative neoplasms
M2 PHARMA-January 24, 2018-QIAGEN wins US FDA clearance for first-ever JAK2 Test for use in diagnosis of additional myeloproliferative neoplasms
Myeloproliferative neoplasms can demonstrate overproduction of one or more of the formed elements from the bone marrow and are said to be able to mimic one another.
Chapters cover the approach to the microscopic evaluation of blood and bone marrow, techniques for assessment, anemia, acute leukemias, myelodysplastic syndromes, myeloproliferative neoplasms, lymphoproliferative disorders, and other conditions.
In its announcement of the new cancer-specialized pharmacy designations, Walgreens noted that the pharmacy staff members at those locations have completed a cancer-focused curriculum of advanced education courses, including courses devoted to colorectal, lung, prostate and breast cancer plus such blood cancers as leukemia, lymphomas, multiple myeloma, myeloproliferative neoplasms and myelodysplatic syndrome.
Staff at these locations have completed a cancer-focused curriculum of advanced education courses, including colorectal, lung, prostate and breast cancer plus blood cancers such as leukemia, lymphomas, multiple myeloma, myeloproliferative neoplasms and myelodysplasia syndrome.
Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms.
Philadelphia-negative myeloproliferative neoplasms (MPNs) were first described 65 years ago.
Leukemia-associated immunophenotypes in myeloid stem cells and abnormal maturation patterns in mature myeloid cells as demonstrated by flow cytometry have recently been used to help diagnose myelodysplastic syndrome (MDS) and myeloproliferative neoplasms.
Myeloproliferative neoplasms From clinic to molecular biology
Myeloproliferative neoplasms (MPNs) can be classified according to the 2008 World Health Organization classification [1] into Philadelphia (Ph) chromosome-negative and positive neoplasms.
According to the 2008 World Health Organization (WHO) classification of hematopoietic tumors, essential thrombocythemia (ET) belongs to BCR-ABL1 negative myeloproliferative neoplasms (MPNs).